IL155273A0 - Pharmaceutical compositions comprising an aplidine compound - Google Patents
Pharmaceutical compositions comprising an aplidine compoundInfo
- Publication number
- IL155273A0 IL155273A0 IL15527301A IL15527301A IL155273A0 IL 155273 A0 IL155273 A0 IL 155273A0 IL 15527301 A IL15527301 A IL 15527301A IL 15527301 A IL15527301 A IL 15527301A IL 155273 A0 IL155273 A0 IL 155273A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- aplidine
- aplidine compound
- compound
- carnitine
- Prior art date
Links
- 229950008499 plitidepsin Drugs 0.000 title abstract 2
- 108010049948 plitidepsin Proteins 0.000 title abstract 2
- -1 aplidine compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0025044A GB0025044D0 (en) | 2000-10-12 | 2000-10-12 | Toxicity protection |
| GB0025209A GB0025209D0 (en) | 2000-10-13 | 2000-10-13 | Treatment of cancers |
| PCT/GB2000/004349 WO2001035974A2 (en) | 1999-11-15 | 2000-11-15 | Aplidine treatment of cancers |
| GB0107373A GB0107373D0 (en) | 2001-03-23 | 2001-03-23 | Aplidine |
| PCT/GB2001/004555 WO2002030441A2 (en) | 2000-10-12 | 2001-10-12 | Treatment of cancers by aplidine in conjunction with a myoprotector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155273A0 true IL155273A0 (en) | 2003-11-23 |
Family
ID=27255931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15527301A IL155273A0 (en) | 2000-10-12 | 2001-10-12 | Pharmaceutical compositions comprising an aplidine compound |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7507766B2 (de) |
| JP (1) | JP2010031043A (de) |
| KR (1) | KR20030038812A (de) |
| CN (1) | CN1479622A (de) |
| AT (1) | ATE299028T1 (de) |
| BR (1) | BR0114604A (de) |
| CZ (1) | CZ2003993A3 (de) |
| ES (1) | ES2243555T3 (de) |
| HK (1) | HK1054191A1 (de) |
| IL (1) | IL155273A0 (de) |
| NO (1) | NO20031673L (de) |
| NZ (1) | NZ525196A (de) |
| PL (1) | PL361179A1 (de) |
| RU (1) | RU2003113210A (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU780417B2 (en) * | 1999-11-15 | 2005-03-17 | Pharma Mar S.A. | Aplidine treatment of cancers |
| CN1761480B (zh) * | 2003-03-12 | 2012-09-26 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
| EP1942944A2 (de) * | 2005-10-31 | 2008-07-16 | Genentech, Inc. | Makrozyklische depsipeptid-antikörper-wirkstoff-konjugate und entsprechende verfahren |
| US8258098B2 (en) * | 2006-02-28 | 2012-09-04 | Pharma Mar, S.A. | Antitumoral treatments |
| US20100240595A1 (en) * | 2007-10-19 | 2010-09-23 | Pharma Mar ,S.A. | Improved Antitumoral Treatments |
| MX2010009697A (es) * | 2008-03-07 | 2010-09-30 | Pharm Mar S A | Tratamientos anticancerigenos mejorados. |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| SI4101855T1 (sl) | 2017-04-27 | 2024-03-29 | Pharma Mar S.A. | Protitumorske spojine |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0048149B1 (de) | 1980-09-12 | 1983-11-30 | University of Illinois Foundation | Antibiotika, Derivate davon, Verfahren zu deren Extraktion und jene enthaltende Ansätze |
| US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
| US4950649A (en) | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
| IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US4948791A (en) | 1989-04-10 | 1990-08-14 | The Board Of Trustees Of The University Of Illinois | Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum |
| GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| DE4120327A1 (de) | 1991-06-20 | 1992-12-24 | Basf Ag | Neue peptide, ihre herstellung und verwendung |
| US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| US5861439A (en) | 1994-11-14 | 1999-01-19 | Alza Corporation | Method for enhanced electrotransport agent delivery |
| ES2102322B1 (es) | 1995-07-13 | 1998-03-01 | Pharma Mar Sa | Procedimiento de preparacion de didemnina a. |
| DK0914116T3 (da) | 1996-05-22 | 2000-11-20 | Protarga Inc | Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere |
| US6156724A (en) | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| US6089373A (en) | 1996-07-03 | 2000-07-18 | Mckechnie Uk Limited | Containers |
| EP0973518B1 (de) | 1996-10-24 | 2006-03-29 | The Board Of Trustees Of The University Of Illinois | Semisynthetisches verfahren zur herstellung von didemninanalogen |
| PT956033E (pt) | 1996-10-24 | 2003-10-31 | Univ Illinois | SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A |
| US6034058A (en) | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
| JP4327260B2 (ja) | 1997-05-07 | 2009-09-09 | フアルマ・マル・エセ・ア | Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| ES2235499T3 (es) | 1998-07-30 | 2005-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| EP1187619A1 (de) | 1999-05-25 | 2002-03-20 | Point Therapeutics, Inc. | Anti-tumor präparate enthaltend boroprolin verbindungen |
| AU780417B2 (en) | 1999-11-15 | 2005-03-17 | Pharma Mar S.A. | Aplidine treatment of cancers |
| US6509315B1 (en) | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
| IL152111A0 (en) | 2000-04-07 | 2003-07-31 | Univ Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| EP1325032A2 (de) | 2000-10-05 | 2003-07-09 | Immunex Corporation | Nectin polypeptide, polynucleotide, verfahren zu deren herstellung und verwendung |
| EP1330254B1 (de) | 2000-10-12 | 2005-07-06 | Pharma Mar, S.A. | BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| WO2003033013A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Use of aplidine for the treatment of pancreatic cancer |
| CN1761480B (zh) | 2003-03-12 | 2012-09-26 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
-
2001
- 2001-10-12 HK HK03106440.0A patent/HK1054191A1/zh unknown
- 2001-10-12 NZ NZ525196A patent/NZ525196A/en unknown
- 2001-10-12 AT AT01974510T patent/ATE299028T1/de not_active IP Right Cessation
- 2001-10-12 US US10/398,835 patent/US7507766B2/en not_active Expired - Fee Related
- 2001-10-12 CN CNA018204740A patent/CN1479622A/zh active Pending
- 2001-10-12 ES ES01974510T patent/ES2243555T3/es not_active Expired - Lifetime
- 2001-10-12 BR BR0114604-1A patent/BR0114604A/pt not_active IP Right Cessation
- 2001-10-12 RU RU2003113210/14A patent/RU2003113210A/ru not_active Application Discontinuation
- 2001-10-12 KR KR10-2003-7005081A patent/KR20030038812A/ko not_active Withdrawn
- 2001-10-12 PL PL01361179A patent/PL361179A1/xx not_active Application Discontinuation
- 2001-10-12 IL IL15527301A patent/IL155273A0/xx unknown
- 2001-10-12 CZ CZ2003993A patent/CZ2003993A3/cs unknown
-
2003
- 2003-04-11 NO NO20031673A patent/NO20031673L/no not_active Application Discontinuation
-
2009
- 2009-11-06 JP JP2009255266A patent/JP2010031043A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030038812A (ko) | 2003-05-16 |
| NO20031673L (no) | 2003-06-12 |
| CN1479622A (zh) | 2004-03-03 |
| US7507766B2 (en) | 2009-03-24 |
| RU2003113210A (ru) | 2004-11-27 |
| PL361179A1 (en) | 2004-09-20 |
| CZ2003993A3 (cs) | 2004-02-18 |
| BR0114604A (pt) | 2003-10-14 |
| JP2010031043A (ja) | 2010-02-12 |
| NZ525196A (en) | 2004-09-24 |
| ES2243555T3 (es) | 2005-12-01 |
| NO20031673D0 (no) | 2003-04-11 |
| US20040010043A1 (en) | 2004-01-15 |
| ATE299028T1 (de) | 2005-07-15 |
| HK1054191A1 (zh) | 2003-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200503A2 (en) | N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them | |
| EP1478406A4 (de) | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung | |
| MXPA04008772A (es) | Composiciones de clorhidrato de naltrexona. | |
| MY129406A (en) | Taste masked liquid pharmaceutical compositions | |
| MY129356A (en) | Electrospun pharmaceutical compositions | |
| HUP0301405A3 (en) | Compositions containing therapeutically active components having enhanced solubility | |
| DK1157037T3 (da) | GCSF-konjugater | |
| AP1450A (en) | Solid oral dosage form comprising a combination of metformin and glibenclamide. | |
| YU75701A (sh) | Farmaceutski preparat | |
| AU7315301A (en) | Compounds and compositions for delivering active agents | |
| ID27503A (id) | Tts yang mengandung antioksidan | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| HUP0304084A3 (en) | Dipeptide derivatives having an terminal 2-thioacyl group as vasopeptidase inhibitors and pharmaceutical compositions containing them | |
| HUP0301240A3 (en) | Pyridazine compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors and pharmaceutical compositions containing them | |
| PL373850A1 (en) | Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same | |
| NZ503308A (en) | Alpha-ketoamide multicatalytic protease inhibitors | |
| IL160523A0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE | |
| HUP0400494A3 (en) | Polyamine analogues as cytotoxic agents and pharmaceutical compositions containing them | |
| IL155273A0 (en) | Pharmaceutical compositions comprising an aplidine compound | |
| HUP0303636A3 (en) | Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient | |
| MXPA03011128A (es) | Composicion de sabor y fragancia. | |
| WO2002030441A3 (en) | Treatment of cancers by aplidine in conjunction with a myoprotector | |
| EP1117681A4 (de) | Peptide | |
| MXPA04006269A (es) | Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes. |